Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Deals

Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform

Fineline Cube Dec 8, 2022

Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...

Company Deals

GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development

Fineline Cube Dec 8, 2022

China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...

Company Drug

Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...

Company Drug

NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...

Company Drug

SciClone’s Danyelza Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...

Company Drug

Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study

Fineline Cube Dec 8, 2022

AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...

Company Deals

Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development

Fineline Cube Dec 7, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...

Company Deals

Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics

Fineline Cube Dec 7, 2022

A new bar was set for the most valuable out-license deal struck by a China-based...

Company Deals

Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology

Fineline Cube Dec 7, 2022

Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series...

Company Deals

Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development

Fineline Cube Dec 7, 2022

Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...

Company Deals

Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing

Fineline Cube Dec 7, 2022

Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...

Company Deals

Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments

Fineline Cube Dec 7, 2022

China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...

Policy / Regulatory

NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions

Fineline Cube Dec 7, 2022

The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...

Company Deals

MaxHealth Biotechnology Completes Series B+ Financing Round

Fineline Cube Dec 7, 2022

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...

Company Drug

MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe

Fineline Cube Dec 7, 2022

Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...

Company Deals

F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again

Fineline Cube Dec 7, 2022

UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...

Company Deals

ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy

Fineline Cube Dec 6, 2022

Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...

Company Drug

Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 6, 2022

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...

Company Deals

Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform

Fineline Cube Dec 6, 2022

Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...

Hospital

Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting

Fineline Cube Dec 6, 2022

The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...

Posts pagination

1 … 597 598 599 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.